Skip to main content
OpenTrials
Completed

NCT Number: NCT03114696

Benefit of IQP-AO-101 for Sleep

The objective of this pilot clinical trial is to evaluate the potential of IQP-AO-101 with respect to sleep-promoting effects in subjects with sleep complaints.

Completed

Looking for future studies?

Notify Me

Key information

Age range

21 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Analyze & Realize

Berlin, 10369, Germany

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 21-65 years old
  • Non-organic moderate sleep complaints in the last year prior to V1, as per investigator's judgement
  • Pittsburgh Sleep Quality Index (PSQI) score 6-15 at V1
  • Body mass index (BMI) 18.5-29.9 kg/m2
  • Generally in good health without clinically significant findings at V1
  • Readiness to comply with study procedures, in particular:
  • Consumption of the IP during the treatment period
  • Wearing activity tracker during the scheduled time periods
  • Filling in the subject diary
  • Keeping habitual diet and level of physical exercise, as well as smoking habits if applicable
  • Women of child-bearing potential:
  • Negative pregnancy testing (ß-HCG in urine) at V1
  • Commitment to use reliable contraception methods during the entire study
  • Written informed consent form

Exclusion criteria

  • Known sensitivity to any components of the investigational product
  • Insomnia (according to investigator's judgement))
  • Substantial daily sleepiness as per investigator's judgement
  • Less than 5 hours sleep per night on average, self-reported at V1
  • Any medical condition associated with sleep disorder as per investigator's judgement (e.g. sleep apnoea, restless legs syndrome, neurological / psychiatric disorder)
  • Any lifestyle and other factors potentially associated with sleep problems as per investigator's judgement (e.g. excessive caffeine intake, shift work, long-distance travelling, significant stressors such as active grieving etc.)
  • History and/or presence of clinically significant dis-ease, which per investigator's judgement could interfere with the results of the study or the safety of the subject:
  • Eating disorders such as anorexia
  • Untreated or non-stabilised metabolic diseases, e.g. diabetes mellitus
  • Untreated or non-stabilised thyroid disorder
  • Untreated or non-stabilised hypertension (regular systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg)
  • Significant gastrointestinal diseases
  • Any other known significant or serious condition / disease that renders subjects ineligible (e.g. history of malignancy within the past 5 years prior to V1, any clinically significant cardiovascular, renal, liver disease etc.)
  • Use of drugs/supplements which could interfere with the results of the study as per investigator's judgement (e.g. melatonin and melatonin derivatives, stimulants, neuroleptics, benzodiazepines, antidepressants, hypnotics) within the last 4 weeks prior to V1 and during the study
  • Behavioural intervention for sleep difficulties in the past 6 months and during the study as per investigator's judgement
  • Deviation of laboratory parameter(s) at V1 that is:
  • clinically significant or
  • >2x ULN (upper limit of normal), unless the deviation is justified by a previously known not clinically relevant condition, e.g. Gilbert's syndrome)
  • Alcohol abuse (men: ≥21 units/week, women: ≥14 units/ week; 1 unit equals approximately 250 mL of beer, 100 mL of wine or 35 mL of spirits)
  • Drug abuse
  • Participation in another study during the last 4 weeks prior to V1 and during the study
  • Women of child-bearing potential: pregnant or breast-feeding
  • Any other reason for exclusion as per investigator's judgment, e.g. insufficient compliance with study procedures

Treatment and study plan

IQP-AO-101

Dietary Supplement

1 dose (sachet) to be consumed 30 - 60 mins before bedtime

Placebo

Dietary Supplement

1 dose to be consumed 30 - 60 mins before bedtime. (Identical to investigational product)

Primary outcomes

  1. Change in mAIS parameters at V5 vs V2

    Time frame: 6 weeks

    Change in modified Athens Insomnia Scale parameters

Secondary outcomes

  1. Change in mAIS parameter at V3 and V4, vs V2

    Time frame: 1 week, 4 weeks

    Change in modified Athens Insomnia Scale parameters

  2. Change in activity tracker sleep parameters

    Time frame: 1 week, 6 weeks

    Use of an activity tracker to monitor sleep and compare against baseline

  3. Change in FAIR-2

    Time frame: 1 week, 4 weeks, 6 weeks

    Change in FAIR-2 at each visit

Other outcomes

  1. Safety parameters assessed by number of subjects with abnormal laboratory values

    Time frame: 1 week, 4 weeks, 6 weeks

    Number of subjects with abnormal laboratory values

  2. Adverse events that are related to treatment

    Time frame: 6 weeks

    Monitoring of adverse effects

Sponsors and collaborators

Lead sponsor

InQpharm Group

Industry

Collaborators

  • Analyze & Realize

Registry information

Official study title

Double-blind, Placebo-controlled, Randomised Pilot Clinical Trial to Explore Benefit and Tolerability of IQP-AO-101 in Healthy Subjects With Sleep Complaints

Important dates

Study start
2017
Primary completion
2017
Study completion
2017
First posted
Apr 14, 2017
Registry last updated
Jan 3, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.